Malignant neoplasm of transverse colon
ICD-10 C18.4 is a billable code used to indicate a diagnosis of malignant neoplasm of transverse colon.
Malignant neoplasm of the transverse colon refers to cancer that originates in the transverse section of the colon, which is the part of the large intestine that runs horizontally across the abdomen. This type of colorectal cancer can present with various symptoms, including abdominal pain, changes in bowel habits, weight loss, and rectal bleeding. Early detection through screening methods such as colonoscopy is crucial, as it can significantly improve prognosis. The staging of colorectal cancer is typically determined using the TNM system, which assesses tumor size (T), lymph node involvement (N), and the presence of metastasis (M). Additionally, microsatellite instability (MSI) testing may be performed to evaluate the tumor's genetic characteristics, which can influence treatment options and prognosis. Surgical approaches, including partial colectomy or total colectomy, are common interventions for localized disease, while chemotherapy and radiation therapy may be indicated for more advanced stages. Accurate coding of C18.4 is essential for appropriate treatment planning and reimbursement.
Detailed pathology reports, treatment plans, and follow-up notes.
Diagnosis and treatment planning for newly diagnosed colorectal cancer patients.
Ensure accurate staging and documentation of treatment response.
Endoscopy reports, biopsy results, and imaging studies.
Screening and surveillance of patients at high risk for colorectal cancer.
Document family history and any findings from colonoscopy.
Used for surgical treatment of malignant neoplasm of the transverse colon.
Operative report detailing the procedure and findings.
Oncology and surgical documentation must align for accurate coding.
Common symptoms include abdominal pain, changes in bowel habits, weight loss, and rectal bleeding. However, some patients may be asymptomatic in early stages.
Diagnosis typically involves a combination of imaging studies, colonoscopy, and biopsy to confirm the presence of cancerous cells.
Microsatellite instability (MSI) indicates a defect in the DNA mismatch repair system and can influence treatment decisions, particularly regarding immunotherapy.
Staging is based on the TNM system, which evaluates tumor size, lymph node involvement, and the presence of metastasis.
